Clofazimine

The clinical treatment of drug-resistant leprosy has long faced the dilemma of limited optional drugs. Clofazimine, as a core variety of anti-mycobacterial drugs, exerts bactericidal effect by interfering with the nucleic acid metabolism of Mycobacterium leprae and inhibiting its protein synthesis. It is not only a key component of the combination chemotherapy for lepromatous leprosy, but also recommended by the WHO for the combination therapy regimen of multidrug-resistant tuberculosis. Meanwhile, it also has clinical application value for some immune-related diseases such as non-tuberculous mycobacterial infections and pustular psoriasis, covering leprosy patients, drug-resistant tuberculosis patients and specific infected populations.

The global anti-leprosy drug market size is stable at around USD 280 million. Among them, clofazimine maintains a steady annual demand growth of 3% to 5% due to its clear clinical positioning and high supply concentration. At present, the global market is dominated by generic drug supply, and the original research products are only circulated in a small number of European and American countries. India and China are the world's most important production bases for clofazimine API, accounting for more than 85% of the global supply in total. For the domestic market, this variety has been included in the National Essential Drug List, with a stable price system. Its clinical supply is dominated by domestic generic drugs, and there is no centralized procurement record yet.

The original research enterprise of clofazimine is Novartis, with the original brand name Lamprene. The core compound patent of clofazimine expired globally in the 1970s. The main dosage form approved for the original research product is soft capsule with the specification of 50mg per capsule, which has been included in the FDA Reference Listed Drug Catalog and China's *Catalog of Reference Preparations for Chemical Drugs*. As of the retrieval time, more than 10 domestic enterprises have obtained CDE registration numbers (status A) for clofazimine API, and 3 enterprises have obtained marketing approval for clofazimine soft capsules, which can fully meet the domestic clinical and generic drug research and development needs. (Data as of October 2024, please refer to the official CDE website for the latest information)

CATO provides a full set of clofazimine impurity reference standards. All products comply with the compliance requirements of multiple regulatory systems such as the Chinese Pharmacopoeia and FDA. Most products are kept in regular stock. For in-stock orders, if placed before 16:00, they can be shipped on the same day, which can efficiently support various scenario needs of API manufacturers such as quality research, generic drug consistency evaluation and compliance declaration.